Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MicroRNA 6075 is a small non-coding RNA molecule that belongs to the microRNA (miRNA) class, typically 21–23 nucleotides in length[5]. Like other miRNAs, it is presumed to regulate gene expression post-transcriptionally by binding to complementary sequences in the 3' untranslated regions of messenger RNAs, resulting in translational suppression or degradation of the target mRNA[5][6]. The specific physiological role and validated gene targets of miR-6075 in humans have yet to be elucidated. However, recent studies have highlighted its significance in oncology: elevated serum levels of miR-6075, particularly when paired with miR-1268b, serve as sensitive and specific biomarkers for early detection of resectable lung cancer[2][3]. Additionally, miR-6075 has been associated with the detection of pancreatic and biliary tract cancers[2][3]. Currently, microRNA 6075 is mainly utilized as a diagnostic biomarker rather than a direct therapeutic target. Its specific functions, validated molecular interactions, and mechanistic contributions to cancer biology remain undetermined. As such, MIR6075 does not fit established categories like "receptor," "enzyme," or "transporter" and should be considered *incorrect* as a classic therapeutic target, given the absence of sufficient functional data and clinical evidence[2][3]. There is a lack of information on drugs directly modulating MIR6075 and its mechanism as a drug target. Whether miR-6075 might be modulated by future oligonucleotide therapies (e.g., antisense, miRNA mimics or inhibitors) remains unknown. There are no notable safety concerns, adverse effect profiles, or patient selection algorithms specific to miR-6075 in clinical use. Aliases given reflect typical miRNA naming conventions for human microRNAs. In summary, MicroRNA 6075 (MIR6075) is a non-coding RNA molecule with emerging relevance as a cancer biomarker, but it is not currently a well-characterized therapeutic target; information on its biological roles and mechanisms is incomplete[2][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on MicroRNA 6075 (MIR6075).